Read the full article here.
This content was originally published by Investopedia. Original publishers retain all rights. It appears here for a limited time before automated archiving. By Investopedia
Novavax has begun human trials, and Merck has joined the race with the acquisition of Themis and collaboration with non-profit IAVI.